Schrödinger, Inc. (NASDAQ:SDGR) Receives $32.90 Consensus Target Price from Brokerages

Shares of Schrödinger, Inc. (NASDAQ:SDGR) have received an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $32.90.

A number of analysts have commented on SDGR shares. BMO Capital Markets lifted their target price on Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Morgan Stanley reduced their target price on Schrödinger from $43.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, August 21st.

Insider Buying and Selling

In related news, insider Margaret Dugan sold 1,531 shares of Schrödinger stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $17.78, for a total transaction of $27,221.18. Following the transaction, the insider now directly owns 13,469 shares in the company, valued at approximately $239,478.82. The trade was a 10.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 8.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Schrödinger

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC lifted its position in Schrödinger by 145.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,413 shares of the company’s stock valued at $27,000 after purchasing an additional 837 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Schrödinger by 49.5% in the second quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after acquiring an additional 703 shares in the last quarter. KBC Group NV lifted its position in shares of Schrödinger by 45.4% in the third quarter. KBC Group NV now owns 2,508 shares of the company’s stock valued at $47,000 after acquiring an additional 783 shares in the last quarter. Quarry LP lifted its position in shares of Schrödinger by 1,150.0% in the third quarter. Quarry LP now owns 2,825 shares of the company’s stock valued at $52,000 after acquiring an additional 2,599 shares in the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of Schrödinger in the second quarter valued at about $66,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Schrödinger Stock Up 2.3 %

SDGR stock opened at $20.84 on Friday. Schrödinger has a twelve month low of $16.67 and a twelve month high of $38.00. The firm has a market cap of $1.52 billion, a PE ratio of -8.91 and a beta of 1.50. The business has a 50 day moving average of $18.63 and a 200 day moving average of $20.18.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). The company had revenue of $35.30 million for the quarter, compared to the consensus estimate of $41.25 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm’s quarterly revenue was down 17.1% on a year-over-year basis. During the same period last year, the business earned ($0.86) EPS. On average, research analysts expect that Schrödinger will post -2.29 earnings per share for the current fiscal year.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.